Vogenx

Gastroparesis is delayed gastric emptying causing chronic nausea, vomiting, and poor oral intake, often linked to diabetic neuropathy or surgery.

Mizagliflozin is an investigational drug candidate that inhibits sodium glucose transporter 1 (SGLT1) to reduce postprandial glucose absorption and insulin secretion.

Post-bariatric hypoglycemia (PBH) involves elevated SGLT1 levels in the intestinal lumen, increasing glucose absorption and insulin secretion after meals.

Vogenx reported positive results from a phase 2 study (VGX 001-011) testing mizagliflozin for post-bariatric hypoglycemia (PBH).

Vogenx completed a phase 2 study of mizagliflozin for post-bariatric hypoglycemia (PBH), with results to be presented at ENDO 2023.

DURHAM, N.C., September 13, 2022, Vogenx Inc. – Vogenx, a clinical-stage developer of novel therapeutics for the treatment of metabolic disease, announced the screening of the first patient in a Phase 2 clinical study of mizagliflozin for the treatment of post bariatric hypoglycemia (“PBH”).

Vogenx initiated a phase 2 study of mizagliflozin for post-bariatric hypoglycemia (PBH), a complication of bariatric surgery.

Vogenx announced positive results from a phase 2 study (VGX 001-011) evaluating mizagliflozin for post-bariatric hypoglycemia (PBH), a complication of bariatric surgery.

VOGENX accelerates its **PBH (Protein-Based Herpes Vaccine)** development pipeline after announcing an **August 2026 initial public offering (IPO)**. The biotech firm secures capital to progress clinical-stage research, targeting herpes prevention through protein-based immunotherapies. The IPO marks a key milestone in scaling vaccine development efforts.

Nov 2026investor.vogenx.comNews article

Vogenx begins a Phase 2b **EMERGE** trial testing **mizagliflozin**, a first-in-class SGLT1 inhibitor with minimal absorption, in patients experiencing recurrent hypoglycemia after bariatric surgery. The randomized, double-blind, placebo-controlled study evaluates two dose levels to assess safety and efficacy. Mizagliflozin targets post-surgical hypoglycemia, a condition affecting some patients following weight-loss procedures.

Oct 2026investor.vogenx.comNews article

Vogenx names Richard Gorman, a thirty-year biopharmaceutical executive, as Chief Commercial Officer. Gorman moves from the company’s Board of Directors to lead commercial strategy and execution. His extensive experience spans drug development and market access in the biopharmaceutical industry.

Oct 2026investor.vogenx.comNews article

Vogenx adds Ken Toombs to its Board of Directors. Toombs, former CEO of PA Consulting, contributes three decades of experience in global professional services and life sciences leadership. His appointment strengthens Vogenx’s strategic advisory capabilities.

Sep 2026investor.vogenx.comNews article